Clinical trial · Interventional
Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing ERCP
Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing Endoscopic Retrograde Cholangio-Pancreatography: Randomized Single Blinded Controlled Study
NCT06409104CI-TRIAL-00077109completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the efficacy and safety of propofol and dexmedetomidine during ERCP regarding hemodynamic, respiratory, sedative and cognitive functions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sedation in ERCP | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
| Propofol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Propofol
- description
- will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion .
- interventionNames
- Drug: Propofol
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine
- description
- will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Bispectral Index sedation Score
- timeFrame
- intraoperative
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Age starting from 21 to 60 years. * Genders eligible for study: males and females * ASA II-III * Undergoing ERCP * 18.5 to 30 kg/m2 Exclusion Criteria: * Patient refusal * Known allergy to drugs used in the study. * Use of any anti-coagulants * Neurological disorders * Advanced liver or kidney disease * Patient with psychiatric disorders
References
Publications (0)
Data not yet available
No reference posted for this study.